1.43
+3.62%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Serina Therapeutics
From its filings with the US Securities and Exchange Commission
Serina Therapeutics is based in Huntsville, Alabama and is incorporated in Alabama. Its shares trade on NYSE under the ticker SER. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $130,000 and a net loss of $19.2m. At that date it held total assets of $7.0m and shareholders' equity of −$37,000.
We are a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and other indications. Our POZ drug delivery technology is designed to enable certain existing drugs and novel drug candidates to be modified in a way that provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs).The Company’s proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline) and is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via easy-to-administer, long-acting subcutaneous injection.
The therapeutic agents in our small molecule product candidates are typically well-understood and marketed drugs that are effective but are limited by pharmacokinetic (“PK”) profiles that can include toxicity, side effects and short half-life. We believe that by using POZ technology, drugs with narrow therapeutic windows can be designed to maintain more desirable and stable levels in the blood. We believe that POZ technology can be applied to small molecules, proteins, ADCs, and other classes of molecules.
Quoted from its 10-K, filed 25 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 29 Nov 2018
- Employees
- 16
- Website
- agexinc.com ↗
- Head office
- 601 GENOME WAY, HUNTSVILLE, AL, 35806
- Incorporated in
- AL
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Balkrishan GillExecutive Chairman of the Board, since 2024$3.0m
- Mr. Steven LedgerChief Executive Officer, Director, since 2024$3.7m
- Mr. Gregory CurhanChief Financial Officer$1.7m
- Dr. Srini TenjarlaSenior Vice President - CMC and Formulation$1.8m
- Dr. Randall MoreadithChief Development Officer$433,880
- Dr. Gregory BaileyIndependent Director$433,114
- Dr. Stephen BrannanIndependent Director
- Mr. Richard MarshallIndependent Director$433,114
- Dr. Jay VenkatesanIndependent Director
- Ms. Karen WilsonIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 22
- Environment
- 21
- Social
- 37
- Governance
- 7
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- AgeX Therapeutics has 17 employees focused on aging therapeutics development.
- AGEX-BAT1 targets Type II diabetes with cell therapy approach.
- AGEX-VASC1 restores vascular support in aged ischemic tissues.
Weaknesses
- AgeX Therapeutics has only 17 employees for a biotechnology company.
- The company's pipeline includes only four therapeutic products.
- The firm's iTR technology is based on telomerase-mediated cellular immortality.
Opportunities
- The aging population in the US presents a growing market for age-related therapies.
- The US biotechnology sector continues to expand with new investments.
- AgeX Therapeutics' AGEX-iTR1547 targets degenerative diseases using iTR technology.
Threats
- The biotechnology industry faces high regulatory hurdles for new therapies.
- Competition in aging therapeutics is increasing globally.
- The company's reliance on telomerase technology may face scientific challenges.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.